ION BEAM APPLICATIONS (IBAB.BR) Stock Fundamental Analysis
EBR:IBAB - Euronext Brussels - BE0003766806 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to IBAB. IBAB was compared to 57 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IBAB while its profitability can be described as average. IBAB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
IBAB had positive earnings in the past year.
In the past year IBAB has reported a negative cash flow from operations.
Of the past 5 years IBAB 4 years were profitable.
In multiple years IBAB reported negative operating cash flow during the last 5 years.
1.2 Ratios
IBAB has a Return On Assets (1.50%) which is comparable to the rest of the industry.
With a decent Return On Equity value of 8.34%, IBAB is doing good in the industry, outperforming 66.67% of the companies in the same industry.
IBAB has a better Return On Invested Capital (11.77%) than 87.72% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IBAB is in line with the industry average of 8.12%.
The last Return On Invested Capital (11.77%) for IBAB is above the 3 year average (6.33%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.5% | ||
| ROE | 8.34% | ||
| ROIC | 11.77% |
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.33%
ROIC(5y)6.79%
1.3 Margins
IBAB has a Profit Margin (1.86%) which is in line with its industry peers.
In the last couple of years the Profit Margin of IBAB has declined.
IBAB has a Operating Margin (5.60%) which is in line with its industry peers.
IBAB's Operating Margin has improved in the last couple of years.
IBAB has a Gross Margin of 33.32%. This is in the lower half of the industry: IBAB underperforms 75.44% of its industry peers.
In the last couple of years the Gross Margin of IBAB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.6% | ||
| PM (TTM) | 1.86% | ||
| GM | 33.32% |
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
2. Health
2.1 Basic Checks
IBAB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
IBAB has more shares outstanding than it did 1 year ago.
IBAB has less shares outstanding than it did 5 years ago.
IBAB has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.48, we must say that IBAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IBAB (1.48) is worse than 61.40% of its industry peers.
IBAB has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
IBAB has a better Debt to Equity ratio (0.23) than 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.48 |
ROIC/WACC1.64
WACC7.16%
2.3 Liquidity
A Current Ratio of 0.95 indicates that IBAB may have some problems paying its short term obligations.
IBAB has a Current ratio of 0.95. This is amonst the worse of the industry: IBAB underperforms 80.70% of its industry peers.
IBAB has a Quick Ratio of 0.95. This is a bad value and indicates that IBAB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.63, IBAB is doing worse than 85.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 195.83% over the past year.
The Earnings Per Share has been growing slightly by 3.99% on average over the past years.
The Revenue has been growing slightly by 6.75% in the past year.
Measured over the past years, IBAB shows a quite strong growth in Revenue. The Revenue has been growing by 12.01% on average per year.
EPS 1Y (TTM)195.83%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%5.14%
Revenue 1Y (TTM)6.75%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%-1.87%
3.2 Future
IBAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 79.05% yearly.
The Revenue is expected to grow by 2.63% on average over the next years.
EPS Next Y267%
EPS Next 2Y133.02%
EPS Next 3Y79.05%
EPS Next 5YN/A
Revenue Next Year16.54%
Revenue Next 2Y11.73%
Revenue Next 3Y8.91%
Revenue Next 5Y2.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.67 indicates a quite expensive valuation of IBAB.
IBAB's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 27.51. IBAB is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 13.04, IBAB is valued correctly.
78.95% of the companies in the same industry are more expensive than IBAB, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.58. IBAB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.67 | ||
| Fwd PE | 13.04 |
4.2 Price Multiples
IBAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBAB is cheaper than 84.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.34 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IBAB's earnings are expected to grow with 79.05% in the coming years.
PEG (NY)0.15
PEG (5Y)10.2
EPS Next 2Y133.02%
EPS Next 3Y79.05%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.42%, IBAB has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.27, IBAB pays a bit more dividend than its industry peers.
Compared to the average S&P500 Dividend Yield of 2.35, IBAB is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.42% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.84% of the earnings are spent on dividend by IBAB. This is a bit on the high side, but may be sustainable.
DP52.84%
EPS Next 2Y133.02%
EPS Next 3Y79.05%
EBR:IBAB (7/15/2025, 5:29:53 PM)
12.2
+0.36 (+3.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.71%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap369.42M
Analysts80
Price Target16.25 (33.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.42% |
Yearly Dividend0.17
Dividend Growth(5Y)N/A
DP52.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.65%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.67 | ||
| Fwd PE | 13.04 | ||
| P/S | 0.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.33 | ||
| P/tB | 4.33 | ||
| EV/EBITDA | 8.34 |
EPS(TTM)0.3
EY2.46%
EPS(NY)0.94
Fwd EY7.67%
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS16.45
BVpS3.66
TBVpS2.82
PEG (NY)0.15
PEG (5Y)10.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.5% | ||
| ROE | 8.34% | ||
| ROCE | 18.95% | ||
| ROIC | 11.77% | ||
| ROICexc | 23.1% | ||
| ROICexgc | 35.13% | ||
| OM | 5.6% | ||
| PM (TTM) | 1.86% | ||
| GM | 33.32% | ||
| FCFM | N/A |
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.33%
ROIC(5y)6.79%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.19%
ROCE(5y)10.93%
ROICexcg growth 3YN/A
ROICexcg growth 5Y53.77%
ROICexc growth 3Y-88.07%
ROICexc growth 5Y51.35%
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
F-Score5
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.65 | ||
| Cap/Depr | 63.41% | ||
| Cap/Sales | 1.49% | ||
| Interest Coverage | 20.73 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.63 | ||
| Altman-Z | 1.48 |
F-Score5
WACC7.16%
ROIC/WACC1.64
Cap/Depr(3y)79.57%
Cap/Depr(5y)64.6%
Cap/Sales(3y)2.05%
Cap/Sales(5y)1.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)195.83%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%5.14%
EPS Next Y267%
EPS Next 2Y133.02%
EPS Next 3Y79.05%
EPS Next 5YN/A
Revenue 1Y (TTM)6.75%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%-1.87%
Revenue Next Year16.54%
Revenue Next 2Y11.73%
Revenue Next 3Y8.91%
Revenue Next 5Y2.63%
EBIT growth 1Y269.56%
EBIT growth 3Y27.16%
EBIT growth 5Y65.71%
EBIT Next Year224.83%
EBIT Next 3Y67.74%
EBIT Next 5Y52.56%
FCF growth 1Y43.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.44%
OCF growth 3YN/A
OCF growth 5YN/A